Compare Amphastar Pharmaceuticals Inc (AMPH) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.32 (market cap $75.52B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 91.4× Amphastar Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MDLZ | |
|---|---|---|
Market Cap | $826.08M | $75.52B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $70.75 |
52-Week Low | $16.87 | $51.51 |
Enterprise Value | $1.22B | $95.62B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Mondelez International (MDLZ) trades at $58.83, up 0.91% today, with a bearish technical signal but strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.67. Revenue grew to $38.54B in 2025, though net income margin compressed to 6.64%. Recent news highlights innovation in packaging and new product launches, alongside a stable dividend of $0.50 per share.
The outlook remains positive with a consensus price target of $68.33, implying 16% upside. Key opportunities include resilient snacking demand and strategic innovations, while risks involve margin pressure from input costs and competitive intensity. Institutional sentiment is bullish, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
